// App-Quantinova.ai

3031 : LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.

Researchers

Presenter

  • Roberto Crocchiolo

Principal Investigators

  • Jean El-Cheikh

  • Norbert Vey

  • Christian Chabannon

  • Didier Blaise

  • Catherine Faucher

  • Claire Oudin

  • Angela Granata

  • Geoffroy Venton

  • Claude Lemarie

  • Diane Coso

  • Reda Bouabdallah

  • Anne Marie Stoppa

Medical Centers

  • Hematology department, Institut Paoli-Calmette, Marseilles,

  • Institut Paoli-Calmettes, Marseille, France

  • Hematology department, Institut Paoli-Calmette, Marseilles,

  • Unite de Transplantation et de Therapie Cellulaire UTTC, Institut Paoli-Calmettes, Marseille, France., Marseille, France

  • HEMATOLOGY, Institut Paoli Calmettes, marseille, France

  • Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France

  • Institut Paoli-Calmettes, Marseille, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Multiple Myeloma

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 34

  • Granulocyte colony-stimulating factor

  • Major histocompatibility complex, class II, DR beta 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Cyclosporine eent

  • fludarabine tablet

  • Filgrastim

  • Mesnex

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved